8-K: PAVmed Secures Nasdaq Extension for Minimum Bid Price Compliance

PAVmed Inc. has been granted an additional 180 calendar days by Nasdaq to regain compliance with the minimum $1 bid price requirement, extending the deadline to January 19, 2026.

Summary

• PAVmed Inc. received a letter from Nasdaq on July 29, 2025, notifying the company of an additional 180 calendar days to regain compliance with the minimum bid price requirement.
• The new deadline for compliance is January 19, 2026.
• The company was initially notified on January 23, 2025, that its common stock closing bid price had been below the $1 per share minimum for 30 consecutive business days through January 22, 2025.
• PAVmed did not regain compliance within the initial 180-day period, which ended on July 22, 2025.
• To regain compliance, the closing bid price of the company's common stock must be at least $1 per share for a minimum of ten consecutive business days during the extended period.
• The Nasdaq notification has no immediate effect on the listing of the company's common stock, which will continue to trade uninterrupted under the symbol PAVM.

Sentiment

Score: 5

Explanation: While the extension provides a temporary reprieve and avoids immediate delisting, the core issue of the stock trading below the minimum bid price persists. This indicates ongoing challenges with market valuation or investor confidence.

Positives

• Nasdaq granted an additional 180-day period, extending the compliance deadline to January 19, 2026, which provides more time to address the bid price deficiency.
• The company's common stock will continue to trade uninterrupted on Nasdaq under the symbol PAVM during this extended period, avoiding immediate delisting.

Negatives

• PAVmed Inc. failed to regain compliance with Nasdaq's minimum $1 bid price requirement within the initial 180-day period, indicating persistent low stock valuation.
• The company's common stock has traded below $1 per share for an extended period, triggering the non-compliance notice and requiring an extension.

Risks

• Failure to regain compliance with the minimum $1 bid price requirement by January 19, 2026, could lead to the delisting of PAVmed's common stock from The Nasdaq Stock Market LLC.
• The company may need to undertake actions such as a reverse stock split to increase its share price, which can be dilutive or negatively perceived by investors.

Future Outlook

The company intends to consider all available options to regain compliance with Nasdaq listing standards.

Management Comments

• The Company intends to consider all available options to regain compliance with the Nasdaq listing standards.

Industry Context

This announcement reflects a common challenge faced by smaller or developing companies listed on major exchanges, where maintaining a minimum share price is a prerequisite for continued listing. Companies in the medical device or biotechnology sector, like PAVmed, often experience stock price volatility due to clinical trial results, regulatory approvals, and market adoption, which can lead to such compliance issues.

Stakeholder Impact

• Shareholders: The extension provides temporary relief from immediate delisting, but the risk of delisting remains. The company's efforts to regain compliance, such as a potential reverse stock split, could impact share structure and perception.

Next Steps

• PAVmed must ensure its common stock's closing bid price is at least $1 per share for a minimum of ten consecutive business days by January 19, 2026.
• The company will consider all available options to regain compliance, which may include a reverse stock split or other corporate actions.

Key Dates

Recommendation

The filing indicates a critical compliance issue, but the granted extension provides a temporary reprieve. While the underlying low stock price is a concern, the immediate threat of delisting has been mitigated. Investors should hold to observe the company's strategy to regain compliance and monitor stock performance leading up to the new January 2026 deadline.

Keywords

PAVMED, PAVM, Nasdaq, listing compliance, minimum bid price, delisting risk, stock market, common stock, 8-K filing